Trials / Recruiting
RecruitingNCT05764720
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (ARTIA-Pancreas)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 134 (estimated)
- Sponsor
- Varian, a Siemens Healthineers Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Daily Adaptive External Beam Radiation Therapy | Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system. |
Timeline
- Start date
- 2023-05-14
- Primary completion
- 2028-03-01
- Completion
- 2030-03-15
- First posted
- 2023-03-13
- Last updated
- 2026-03-16
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05764720. Inclusion in this directory is not an endorsement.